Mechanisms of the development of androgen independence in prostate cancer
- 27 January 2005
- journal article
- review article
- Published by Springer Nature in World Journal of Urology
- Vol. 23 (1) , 1-9
- https://doi.org/10.1007/s00345-004-0473-1
Abstract
The effectiveness of androgen ablation in the management of advanced prostate cancer is of limited duration, with the median length of response being only 18–24 months. The transition of the prostate cancer cell to an androgen independent phenotype is a complex process that involves selection and outgrowth of pre-existing clones of androgen-independent cells (clonal selection) as well as adaptive up-regulation of genes that help the cancer cells survive and grow after androgen ablation (adaptation). These two mechanisms share an important pre-requisite characteristic: prostate cancers are heterogeneous tumours comprised of various subpopulations of cells that respond differently to androgen withdrawal therapy. This tumour heterogeneity may reflect either a multifocal origin, adaptation to environmental stimuli, and/or genetic instability of the initial cancer. This review will reexamine the different mechanisms that enable prostate cancer cells to proliferate in an androgen depleted environment.Keywords
This publication has 92 references indexed in Scilit:
- Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)Clinical Cancer Research, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Androgen receptor gene amplification and protein expression in hormone refractory prostate cancerBritish Journal of Cancer, 2003
- Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5The Prostate, 2000
- Lack of Association between Enhanced TRPM-2/Clusterin Expression and Increased Apoptotic Activity in Sex-Hormone-Induced Prostatic Dysplasia of the Noble RatThe American Journal of Pathology, 1998
- Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate CancerNew England Journal of Medicine, 1995
- Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomasZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- The IGF Axis in the ProstateHormone and Metabolic Research, 1994
- The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosisKidney International, 1991